Show simple item record

dc.contributor.authorBermejo, Mercedes 
dc.contributor.authorAmbrosioni, Juan
dc.contributor.authorBautista, Guiomar
dc.contributor.authorCliment, Núria
dc.contributor.authorMateos, Elena 
dc.contributor.authorRovira, Cristina
dc.contributor.authorRodriguez‑Mora, Sara 
dc.contributor.authorLopez-Huertas, Maria Rosa 
dc.contributor.authorGarcía-Gutiérrez, Valentín
dc.contributor.authorSteegmann, Juan Luis
dc.contributor.authorDuarte, Rafael
dc.contributor.authorCervantes, Francisco
dc.contributor.authorPlana, Montserrat
dc.contributor.authorMiró, José M
dc.contributor.authorAlcamí, José 
dc.contributor.authorCoiras, Mayte
dc.identifier.citationBiochem Pharmacol. 2018 Oct;156:248-264.es_ES
dc.description.abstractCurrent antiretroviral treatment (ART) may control HIV-1 replication but it cannot cure the infection due to the formation of a reservoir of latently infected cells. CD4+ T cell activation during HIV-1 infection eliminates the antiviral function of the restriction factor SAMHD1, allowing proviral integration and the reservoir establishment. The role of tyrosine kinases during T-cell activation is essential for these processes. Therefore, the inhibition of tyrosine kinases could control HIV-1 infection and restrict the formation of the reservoir. A family of tyrosine kinase inhibitors (TKIs) is successfully used in clinic for treating chronic myeloid leukemia (CML). The safety and efficacy against HIV-1 infection of five TKIs was assayed in PBMCs isolated from CML patients on prolonged treatment with these drugs that were infected ex vivo with HIV-1. We determined that the most potent and safe TKI against HIV-1 infection was dasatinib, which preserved SAMHD1 antiviral function and avoid T-cell activation through TCR engagement and homeostatic cytokines. Imatinib and nilotinib showed lower potency and bosutinib was quite toxic in vitro. Ponatinib presented similar profile to dasatinib but as it has been associated with higher incidence of arterial ischemic events, dasatinib would be the better choice of TKI to be used as adjuvant of ART in order to avoid the establishment and replenishment of HIV-1 reservoir and move forward towards an HIV cure.es_ES
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2013-44677-R, SAF2016-78480-R, FIS PI12/00506, and FIS PI12/00969); the Spanish AIDS Research Network RD16CIII/0002/0001 that is included in Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2016-2020, Instituto de Salud Carlos III, European Region Development Fund (ERDF); Bristol-Myers Squibb [BMS AI471-041]. The work of Elena Mateos is supported by the Spanish Ministry of Economy and Competitiveness SAF2016-78480-R. The work of María Rosa López-Huertas is financed by ISCIII-Subdirección General de Evaluacion and European Funding for Regional Development (FEDER) and by Spanish Ministry of Economy and Competitiveness (PIE 13/00040). Dr. Montserrat Plana is a researcher at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and is supported by the Spanish Health Institute Carlos III (ISCIII) and the Health Department of the Catalan Government (Generalitat de Catalunya, Spain). Dr. Juan Ambrosioni developed this work in the framework of a ‘Juan de la Cierva 2012’ post-doctoral program, Ministerio de Competitividad. Dr. Jose M. Miró received a personal 80:20 research grant from IDIBAPS (Barcelona, Spain), 2017-2019.es_ES
dc.publisherElsevier es_ES
dc.subjectChronic myeloid leukemiaes_ES
dc.subjectSrc tyrosine kinaseses_ES
dc.subjectViral reservoires_ES
dc.subject.meshCell Proliferationes_ES
dc.subject.meshCell Survival es_ES
dc.subject.meshHEK293 Cells es_ES
dc.subject.meshHIV-1 es_ES
dc.subject.meshHumans es_ES
dc.subject.meshLeukocytes, Mononuclear es_ES
dc.subject.meshProtein Kinase Inhibitors es_ES
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive es_ES
dc.titleEvaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitorses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España) 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderGovernment of Catalonia (España) 
dc.identifier.journalBiochemical pharmacologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FIS PI12 / 00506
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FIS PI12 / 00969
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16CIII / 0002/0001
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BMS AI471-041
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PIE 13/00040
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional